Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 62Neoplasms 52Neoplasm Metastasis 49Leukemia, Myeloid, Acute 48Colorectal Neoplasms 48Breast Neoplasms 44Prostatic Neoplasms 38Multiple Myeloma 34Ovarian Neoplasms 32Recurrence 29Melanoma 28Pancreatic Neoplasms 27Lymphoma, Non-Hodgkin 26Squamous Cell Carcinoma of Head and Neck 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Myelodysplastic Syndromes 22Endometrial Neoplasms 22Triple Negative Breast Neoplasms 21Glioblastoma 20Carcinoma, Renal Cell 20Lung Neoplasms 19Advanced Solid Tumors 19Stomach Neoplasms 18Small Cell Lung Carcinoma 18Sarcoma 18Carcinoma, Hepatocellular 17Brain Neoplasms 17Lymphoma, B-Cell 14Esophageal Neoplasms 13Advanced Solid Tumor 13

Interventions

dapagliflozin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hyperinsulinism × 30 days × Clear all
NCT05989347 2026-05-22

Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant With Neoadjuvant Therapy

Yale University

Phase 1 Recruiting
20 enrolled
Breast

Breast Neoplasms, Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡